Self-Monitoring Blood Glucose Monitoring Devices Market size to cross USD 59.1 Billion by 2034

Selbyville, DE. - The global self-monitoring blood glucose monitoring devices market was estimated at USD 19.8 billion in 2024 and is expected to grow from USD 21.6 billion in 2025 to USD 59.1 billion in 2034, at a CAGR of 11.8%, according to the latest report published by Global Market Insights Inc.  

The global surge in type 1 and type 2 diabetes cases, particularly in emerging markets, is driving demand for convenient and reliable SMBG devices for daily glucose tracking. As sedentary lifestyles, unhealthy diets, and rising obesity rates contribute to a higher incidence of diabetes, more individuals are being diagnosed at younger ages and across wider demographics.  

Key Insights

Market Size & Growth:

• 2024 Market Size: USD 19.8 billion
• 2025 Market Size: USD 21.6 billion
• 2034 Forecast Market Size: USD 59.1 billion
• CAGR (2025–2034): 11.8%  

Regional Insights:

• Largest Market: North America
• Fastest Growing Market: Asia Pacific
• Emerging Countries: India, Brazil, Mexico, South Africa

Key Growth Drivers:

1. Growing awareness of preventive healthcare: Patients are increasingly proactive about managing their health, leading to a rise in home-based glucose monitoring to avoid complications and hospital visits.  
2. Technological advancements in SMBG devices: Modern glucose meters now offer features like Bluetooth connectivity, app integration, smaller sample requirements, and faster results, enhancing user experience and compliance.  
3. Aging population and chronic disease burden: The rise in elderly populations and associated chronic conditions is boosting demand for easy-to-use, self-monitoring solutions to manage glucose levels independently.  
4. Expansion of reimbursement policies: In several countries, improved insurance coverage and reimbursement for diabetes management tools are making SMBG devices more accessible and affordable for patients.  
5. Shift toward personalized and remote care: The integration of SMBG devices with digital health platforms and telemedicine is empowering healthcare providers to offer data-driven, personalized treatment and remote monitoring.  

Key Players:

• F. Hoffmann-La Roche led the market with over 7.1% share in 2024.  
• Some of the top players in this market include LifeScan, Sinocare, Abbott Laboratories, F. Hoffmann-La Roche, and Ascensia Diabetes Care Holdings, which together held a 21.6% share in 2024.  

Key Challenges:

1. High cost of devices and test strips: Although glucose meters themselves may be affordable, the recurring cost of test strips and lancets can be a financial burden for patients in low- and middle-income countries.  
2. Limited awareness and education: In many regions, particularly rural and underserved areas, there is still limited awareness about the importance of regular blood glucose monitoring.  
3. Accuracy and reliability concerns: Some users express concerns over the accuracy and consistency of readings from certain low-cost or unregulated devices.  
4. User compliance and monitoring fatigue: Many patients struggle with the discipline of frequent testing, especially those newly diagnosed or managing type 2 diabetes with lifestyle changes.  
5. Regulatory and quality challenges: Varying regulatory standards across countries pose challenges for manufacturers aiming to enter new markets.

Browse key industry insights spread across 132 pages with 181 market data tables and figures from the report, “Self-Monitoring Blood Glucose Monitoring Devices Market Size - By Product, By Application, By End Use, Growth Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/self-monitoring-blood-glucose-devices-market  

Rising Demand for Consumables

The consumables segment held a notable share in 2024, driven by test strips, lancets, and control solutions. As these items are essential for daily monitoring, their demand remains consistently high, driving steady market growth. Test strips dominate consumables sales due to their frequent replacement cycles. As consumers seek more accurate and convenient testing, companies are innovating to produce strips that require smaller blood samples and deliver faster results. The consumables segment’s expansion is critical for maintaining patient adherence, and it continues to attract substantial investment from industry players aiming to secure long-term customer loyalty.  

Rising Prevalence of Type 2 Diabetes

The type 2 diabetes segment generated significant revenues in 2024, reflecting the global rise in lifestyle-related diabetes cases. Patients with type 2 diabetes often require regular glucose monitoring to manage their condition effectively alongside diet and medication. This segment is growing rapidly as awareness about disease management improves and healthcare providers emphasize the importance of glycemic control in preventing complications. The affordability and ease of use of SMBG devices for type 2 diabetes patients make them indispensable tools.  

Homecare to Gain Traction

The homecare segment held a significant share in 2024, driven by the trend toward patient-centered and remote healthcare management. More individuals prefer monitoring their blood glucose levels from the comfort of their homes, motivated by convenience, privacy, and the ongoing expansion of telehealth services. This segment benefits from technological advancements, including smartphone-compatible devices and digital health platforms that enable real-time data sharing with healthcare professionals. Homecare adoption also aligns with the increasing emphasis on chronic disease management outside clinical settings.  

North America to Emerge as a Lucrative Region

North America self-monitoring blood glucose monitoring devices market generated a notable share in 2024. Strong healthcare infrastructure, high diabetes prevalence, and widespread insurance coverage contribute to robust demand for these devices. Consumers in this region prioritize accuracy, convenience, and integration with digital health ecosystems, which has pushed manufacturers to innovate rapidly. Additionally, the presence of major industry players and a well-established regulatory environment ensures high-quality standards and product reliability.  

Major players in the self-monitoring blood glucose monitoring devices market are All Medicus, DarioHealth, B. Braun Melsungen, Ypsomed Holding, Sanofi, Bionime Corporation, AgaMatrix, Nova Biomedical, LifeScan, Arkray, Omnis Health, Sinocare, Abbott Laboratories, F. Hoffmann-La Roche, and Ascensia Diabetes Care Holdings.  

To strengthen their market foothold, companies in the self-monitoring blood glucose monitoring devices market are focusing heavily on innovation, partnerships, and patient engagement. Product development emphasizes accuracy, ease of use, and connectivity, with many manufacturers launching app-enabled meters that integrate with broader digital health platforms. Strategic collaborations with healthcare providers and insurance companies are expanding device accessibility through reimbursement schemes and bundled care programs. Companies are also investing in educational initiatives to improve patient literacy and adherence, especially in emerging markets.